Free Trial
NYSE:IKT

Inhibikase Therapeutics 3/27/2024 Earnings Report

Inhibikase Therapeutics logo
$2.14 -0.11 (-4.67%)
As of 03:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Inhibikase Therapeutics EPS Results

Actual EPS
-$0.63
Consensus EPS
-$0.78
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Inhibikase Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Inhibikase Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Inhibikase Therapeutics Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Inhibikase Therapeutics announces appointment of McIntyre as CFO
See More Inhibikase Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibikase Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibikase Therapeutics and other key companies, straight to your email.

About Inhibikase Therapeutics

Inhibikase Therapeutics (NYSE:IKT), a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

View Inhibikase Therapeutics Profile

More Earnings Resources from MarketBeat